The estimated Net Worth of Bros. Advisors Lp Baker Bro... is at least $701 million dollars as of 18 November 2016. Bros Bro owns over 1,760,495 units of BeiGene Ltd stock worth over $700,590,844 and over the last 9 years Bros sold BGNE stock worth over $0.
Bros has made over 3 trades of the BeiGene Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently Bros bought 1,760,495 units of BGNE stock worth $56,335,840 on 18 November 2016.
The largest trade Bros's ever made was buying 1,912,680 units of BeiGene Ltd stock on 8 February 2016 worth over $45,904,320. On average, Bros trades about 1,396,464 units every 71 days since 2016. As of 18 November 2016 Bros still owns at least 3,317,977 units of BeiGene Ltd stock.
You can see the complete history of Bros Bro stock trades at the bottom of the page.
Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd.... et Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
BeiGene Ltd executives and other stock owners filed with the SEC include: